Tracxn's proprietary #taxonomy brings to you top #BusinessModels in Life Sciences rebrand.ly/n1qpm1h Get our free reports on #PracticeArea or #sector of your interest to your mailbox regularly https://rb.gy/cx2upn

1. TRACXN TOP BUSINESS MODELS REPORT
May 17, 2021
LIFE SCIENCES

2. Life Sciences - Top Business Models Report Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Contents
Life Sciences Funding - Overview 3
Top Funded Business Models 4
One pagers 9
Appendix 59
2

3. Life Sciences - Top Business Models Report Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Funding in last 1 year
3
Oncology $19.3B
Genomics $14.0B
Life Sciences Platforms and Tools $9.2B
Life Sciences Tech $6.2B
Diagnostics (by Technology) $5.4B
Infectious Diseases $4.7B
Y-o-Y Funding
Top Investors by Funding Rounds
Seed
Stage
Y Combinator
Illumina
HTGF
20
6
5
Early
Stage
Casdin Capital
RA Capital Management
Orbimed
27
27
23
Late
Stage
Orbimed
RA Capital Management
Fidelity Investments
36
29
21
Funding by Geography
Top Feeds by $ Funding
Top Funding Rounds
United States (68%)
China (14%)
United Kingdom (5%)
Germany (2%)
Israel (2%)
Switzerland (2%)
Canada (1%)
Others (6%)
$ Funding # Rounds
Sana Biotechnology
(2018, United States)
$821M - Series D
ElevateBio
(2018, United States)
$525M - Series C
Insitro
(2018, United States)
$400M - Series C
Indigo
(2013, United States)
$360M - Series F
CureVac
(2000, Germany)
$343M - Series F
Adagio
(2020, United States)
$336M - Series C
XtalPi
(2014, United States)
$319M - Series C
LianBio
(1999, China)
$310M - Series D
Tizona Therapeutics
(2015, United States)
$300M - Series D
Zymergen
(2013, United States)
$300M - Series D
Pionyr Immuntherapeutics
(2015, United States)
$275M - Series C
Nanopore
(2005, United Kingdom)
$271M - Series H

4. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Top Funded Business Models - last 1 year (1/5)
4
Rank Business Model $ Funding # Rounds Top Funding Round Details
1<> 0
Life Sciences Platforms and Tools > Research
Services
$4.3B 231 Indigo | $360M | Series F Link
2▲4 Cheminformatics for Drug Discovery $2.4B 30 Insitro | $400M | Series C Link
3▼1 Cancer Drugs $1.5B 44 VelosBio | $137M | Series B Link
4▲16 Gene Editing Platforms $1.3B 23 Tessera Thera.. | $230M | Series B Link
5▲4 Hematologic Cancer Drugs $1.1B 11 ElevateBio | $525M | Series C Link
6▼3 Cancer Diagnostic Tests $911M 18 Freenome | $270M | Series C Link
7▲44 Immunology > Drugs > Autoimmune Diseases $880M 19 D3 Bio | $200M | Series A Link
8▲58
Life Sciences Platforms and Tools > Research
Services > Proteomics
$867M 17 Somalogic | $212M | Series E Link
9▲84 Ophthalmology > Drugs > Retinal Disorders $856M 15 CureVac | $343M | Series F Link
10▲5 Life Sciences Platforms and Tools > Diversified $783M 18 PHC Holdings | $182M | Series D Link
* Rank is based on $Invested in last 1 year in the Business Model. ▲- Indicates change in Rank from previous 1 year.

5. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Top Funded Business Models - last 1 year (2/5)
5
Rank Business Model $ Funding # Rounds Top Funding Round Details
11▲13 Inflammatory Diseases Drugs $691M 27 Flame Bioscie.. | $100M | Series B Link
12▲308 COVID-19 Drugs $681M 14 Adagio | $336M | Series C Link
13▼9 Neurodegenerative Disorders Drugs $606M 37 Annexon | $102M | Series D Link
14▼2 Genomic Biomarker Discovery Research $593M 8 Freenome | $270M | Series C Link
15▲79 Proteomic Based Diagnostic Tests $526M 7 Somalogic | $212M | Series E Link
16▲25
Infectious Diseases > Drugs > Bacterial > Drug
Resistant Infections
$499M 16 Everest Medic.. | $260M | Series C Link
17▼6 Nucleic Acid Sequencing Equipments $445M 7 Nanopore | $271M | Series H Link
18▲153
Genomics > Genomics Services > Genome
Engineering
$439M 7 Artiva | $120M | Series B Link
19▲17 At-Home Preventive Genetic Test Kits $436M 7 Everly Wellness | $175M | Series D Link
20▼10 Robotic Surgery Instruments $425M 14 Memic Surgery | $96.0M | Series D Link
* Rank is based on $Invested in last 1 year in the Business Model. ▲- Indicates change in Rank from previous 1 year.

6. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Top Funded Business Models - last 1 year (3/5)
6
Rank Business Model $ Funding # Rounds Top Funding Round Details
21▲5 Ophthalmology Drugs $392M 34 CureVac | $343M | Series F Link
22▲124 Precision Medicine Software $386M 6 3DMed | $224M | Series D Link
23▲23 High-Throughput DNA Sequencing Instruments $381M 2 Nanopore | $271M | Series H Link
24▼5 Antibacterial Drugs $380M 26 Everest Medic.. | $260M | Series C Link
25▼8
Life Sciences Platforms and Tools > Research
Services > Genomics
$367M 23 Caribou Biosc.. | $115M | Series C Link
26-- Rare Autoimmune Disorders Drugs $360M 4 Forge Biologics | $120M | Series B Link
27▲31 Proteomics Based Drug Discovery Software $355M 10 Eikon | $148M | Series A Link
28▲2
Diagnostics (by Technology) > Diagnostic Assays and
Systems > In vitro Diagnostics > Multi-om..
$352M 2 Freenome | $270M | Series C Link
29▼21 Diabetes Drugs $333M 22 Kriya Therap.. | $85.6M | Series A Link
30-- Immunology > Drugs > GvHD $327M 4 Orca Bio | $192M | Series D Link
* Rank is based on $Invested in last 1 year in the Business Model. ▲- Indicates change in Rank from previous 1 year.

7. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Top Funded Business Models - last 1 year (4/5)
7
Rank Business Model $ Funding # Rounds Top Funding Round Details
31--
Cardiac and Vascular Disorders > Drugs > Valvular
Disorders
$313M 2 LianBio | $310M | Series D Link
32▲118 R&D Workflow Management Solutions $295M 3 Benchling | $200M | Series E Link
33▼1 Rare Neurological Disease Drugs $294M 7 Neurogene | $115M | Series B Link
34▲8 Oncology > Drugs > Breast Cancer $289M 5 Olena Pharma | $87.4M | Series C Link
35▲69
Diagnostics (by Technology) > Diagnostic Software >
Imaging > Digital Pathology
$282M 10 PAIGE | $100M | Series C Link
36▲107 Digital Pathology Image Analysis Software $277M 8 PAIGE | $100M | Series C Link
37▼16 Valvular Disorder Therapy Devices $275M 13 Shanghai New .. | $100M | Series C Link
38▲16
Diagnostics (by Technology) > Diagnostic Assays and
Systems > In vitro Diagnostics > Cell or ..
$273M 3 Thrive Earlie.. | $257M | Series B Link
39▲98 Genomics Based Drug Discovery Software $270M 8 LinkDoc | $102M | Series D Link
40▼5
Life Sciences Platforms and Tools > Research
Services > Animal Models
$268M 5 Biocytogen | $142M | Series D Link
* Rank is based on $Invested in last 1 year in the Business Model. ▲- Indicates change in Rank from previous 1 year.

8. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Top Funded Business Models - last 1 year (5/5)
8
Rank Business Model $ Funding # Rounds Top Funding Round Details
41▼4 Genomics > Genomics Research > Research Models $267M 2 Biocytogen | $142M | Series D Link
42▼37 Rare Metabolic Disorder Drugs $267M 18 Goldfinch | $100M | Series B Link
43▲33 Molecular Modeling Solutions $260M 10 Cellarity | $123M | Series B Link
44▲313
Genomics > Applied Genomics > Clinical Genomics >
Diagnostics > Sequencing-based > Genetic Di..
$257M 6 Sema4 | $121M | Series C Link
45▲491 Pharmocogenomic Tests $250M 4 Caris Lif.. | $235M | Unattributed Link
46▲32 Genetic Engineering Technologies $249M 11 Senti Bioscie.. | $105M | Series B Link
47▼24 Neromuscular Disorder Drugs $247M 7 Dyne Therapeu.. | $116M | Series B Link
48▲204 Wound Healing Drugs $239M 11 Endeavor Bio.. | $62.0M | Series A Link
49▲314
Gastroenterology > Drugs > Bowel Disorders >
Inflammatory Bowel Disorders
$232M 6 Prometheus Bi.. | $130M | Series D Link
50▲27 Metabolic Diseases > Drugs > Endocrine disorders $216M 4 VISEN Pharmac.. | $150M | Series B Link
* Rank is based on $Invested in last 1 year in the Business Model. ▲- Indicates change in Rank from previous 1 year.

9. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
Life Sciences Platforms and Tools >
Research Services
01
9
Back to index
Life Sciences Platforms and Tools (Illumina)
(# Cos: 9346 | $48.0B)
Research Services (Ginkgo Bioworks)
(# Cos: 4917 | $32.8B)
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$4.3B (▲28.9%)
231(▼10.1%)
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
409
$32.8B
2395
242
4917
198
Ginkgo Bioworks
(2009, United States, $796M)
Human Longevity
(2013, United States, $330M)
Horizon Discovery
(2007, United Kingdom, $46.3M)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.
Indigo (2013, United States)
$360M - Series F - Jun 2020
Zymergen (2013, United States)
$300M - Series D - Sep 2020
Tessera Thera.. (2018, United States)
$230M - Series B - Jan 2021
Somalogic (1999, United States)
$212M - Series E - Dec 2020
Lepu Biotechnology (2018, China)
$186M - Series B - Aug 2020
Biocytogen (2008, United States)
$142M - Series D - Sep 2020
Vividion Ther.. (2016, United States)
$135M - Series C - Feb 2021
View all 231 Funding Rounds on Tracxn Platform

10. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
Cheminformatics for Drug Discovery
02
10
Back to index
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$2.4B (▲432%)
30(▲57.9%)
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
19
$4.1B
132
5
257
19
Life Sciences Tech (Veeva Systems)
(# Cos: 4054 | $19.2B)
Research & Development (Medidata)
(# Cos: 3250 | $16.0B)
Drug Discovery (Illumina)
(# Cos: 934 | $8.6B)
Cheminformatics (Recursion)
(# Cos: 257 | $4.1B)
Recursion
(2013, United States, $455M)
Insitro
(2018, United States, $543M)
Atomwise
(2012, United States, $175M)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.
Insitro (2018, United States)
$400M - Series C - Mar 2021
XtalPi (2014, United States)
$319M - Series C - Sep 2020
Recursion (2013, United States)
$246M - Series D - Nov 2020
Exscientia (2012, United Kingdom)
$225M - Series D - Apr 2021
ValoHealth (2019, United States)
$190M - Series B - Jan 2021
ATAI (2018, Germany)
$157M - Series D - Mar 2021
Insitro (2018, United States)
$143M - Series B - May 2020
View all 30 Funding Rounds on Tracxn Platform

11. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
VelosBio (2017, United States)
$137M - Series B - Jul 2020
Boundless Bio (2018, United States)
$106M - Series B - Apr 2021
TScan Therape.. (1995, United States)
$100M - Series C - Jan 2021
Gracell Bio (2017, China)
$100M - Series C - Oct 2020
Wuhan Binhui Biotechn.. (2010, China)
$94.9M - Series B - Feb 2021
Bolt Biothera.. (2015, United States)
$93.5M - Series C - Jul 2020
Shattuck Labs (2016, United States)
$83.0M - Series C - Jun 2020
View all 44 Funding Rounds on Tracxn Platform
Cancer Drugs
03
11
Back to index
Oncology (Adaptive Biotechnologies)
(# Cos: 4068 | $85.2B)
Drugs (Moderna)
(# Cos: 2628 | $66.0B)
Pan Cancer (GigaGen)
(# Cos: 347 | $7.2B)
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$1.5B (▼6.4%)
44(▼15.4%)
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
24
$7.2B
223
41
347
44
GigaGen
(2011, United States, $36.1M)
Fusion Pharmaceuticals
(2014, Canada, $171M)
TScan Therapeutics
(1995, United States, $180M)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.

12. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
Gene Editing Platforms
04
12
Back to index
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$1.3B (▲410%)
23(▲53.3%)
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
5
$1.9B
54
2
84
16
Genomics (Illumina)
(# Cos: 6764 | $72.3B)
Enabling Technologies (10X Genomics)
(# Cos: 1547 | $16.3B)
Technology Platforms (Moderna)
(# Cos: 346 | $9.0B)
Gene Editing (Horizon Discovery)
(# Cos: 84 | $1.9B)
Horizon Discovery
(2007, United Kingdom, $46.3M)
Locus Biosciences
(2015, United States, $32.3M)
Vineti
(2016, United States, $151M)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.
Tessera Thera.. (2018, United States)
$230M - Series B - Jan 2021
Graphite Bio (2020, United States)
$151M - Series B - Mar 2021
Scribe Therap.. (2018, United States)
$100M - Series B - Mar 2021
Locana (2016, United States)
$100M - Series B - Dec 2020
Korro Bio (2018, United States)
$91.5M - Series A - Sep 2020
Remix Therape.. (2019, United States)
$81.0M - Series A - Dec 2020
BioHeng (2017, China)
$80.0M - Series B - Mar 2021
View all 23 Funding Rounds on Tracxn Platform

13. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
ElevateBio (2018, United States)
$525M - Series C - Mar 2021
Orca Bio (2016, United States)
$192M - Series D - Jul 2020
Monte Rosa Th.. (2020, United States)
$96.0M - Series B - Sep 2020
Monte Rosa Th.. (2020, United States)
$95.0M - Series C - Mar 2021
Ossium Health (2016, United States)
$63.0M - Series B - Mar 2021
Priothera (2020, Ireland)
$35.5M - Series A - Oct 2020
Monte Rosa Th.. (2020, United States)
$32.5M - Series A - May 2020
View all 11 Funding Rounds on Tracxn Platform
Hematologic Cancer Drugs
05
13
Back to index
Oncology (Adaptive Biotechnologies)
(# Cos: 4068 | $85.2B)
Drugs (Moderna)
(# Cos: 2628 | $66.0B)
Blood Cancer (Kiadis Pharma)
(# Cos: 81 | $3.7B)
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$1.1B (▲150%)
11( <> 0% )
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
8
$3.7B
61
18
81
10
Kiadis Pharma
(1997, Netherlands, $33.0M)
ASLAN Pharmaceuticals
(2010, Singapore, $100M)
Syros Pharmaceuticals
(2012, United States, $124M)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.

14. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
Freenome (2014, United States)
$270M - Series C - Aug 2020
Color (2013, United States)
$167M - Series D - Jan 2021
Genecast (2016, China)
$149M - Series E - Oct 2020
Personal Genome (2010, United States)
$103M - Series C - Feb 2021
NovellusDx (2011, Israel)
$57.0M - Series C - Sep 2020
Earli (2018, United States)
$40.0M - Series A - Jan 2021
Jiyinga Technology (2015, China)
$38.0M - Series B - Nov 2020
View all 18 Funding Rounds on Tracxn Platform
Cancer Diagnostic Tests
06
14
Back to index
Oncology (Guardant Health)
(# Cos: 4068 | $85.2B)
In-Vitro Diagnostic Tests (Adaptive
Biotechnologies)
(# Cos: 1028 | $15.1B)
Pan Cancer (GRAIL)
(# Cos: 191 | $5.3B)
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$911M (▲14.5%)
18(▼25%)
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
22
$5.3B
124
9
191
19
GRAIL
(2016, United States, $2.0B)
Color
(2013, United States, $391M)
Freenome
(2014, United States, $508M)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.

15. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
D3 Bio (2018, China)
$200M - Series A - Nov 2020
Ventyx Biosci.. (2018, United States)
$114M - Series D - Mar 2021
Annexon (2011, United States)
$102M - Series D - Jul 2020
Regor (2018, United States)
$90.0M - Series B - Feb 2021
Esker Therape.. (2021, United States)
$70.0M - Series A - May 2021
Q32 Bio (2018, United States)
$60.0M - Series B - Oct 2020
CatalYm (2016, Germany)
$59.3M - Series B - Nov 2020
View all 19 Funding Rounds on Tracxn Platform
Immunology > Drugs > Autoimmune
Diseases
07
15
Back to index
Immunology (DBV Technologies)
(# Cos: 786 | $17.4B)
Drugs (GigaGen)
(# Cos: 655 | $16.6B)
Autoimmune Diseases (Moderna)
(# Cos: 85 | $5.1B)
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$880M (▲538%)
19(▲111%)
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
2
$5.1B
56
10
85
16
Moderna
(2010, United States, $2.8B)
X-37
(2019, United States, $14.5M)
Immutep
(2002, France)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.

16. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
Somalogic (1999, United States)
$212M - Series E - Dec 2020
AbSci (2011, United States)
$125M - Series E - Mar 2021
Atomwise (2012, United States)
$123M - Series B - Aug 2020
Somalogic (1999, United States)
$121M - Series E - Nov 2020
Amunix (2006, United States)
$117M - Series B - Mar 2021
Nautilus Biot.. (2016, United States)
$76.1M - Series B - May 2020
AbSci (2011, United States)
$70.0M - Series E - Oct 2020
View all 17 Funding Rounds on Tracxn Platform
Life Sciences Platforms and Tools > Research
Services > Proteomics
08
16
Back to index
Life Sciences Platforms and Tools (Illumina)
(# Cos: 9346 | $48.0B)
Research Services (Ginkgo Bioworks)
(# Cos: 4917 | $32.8B)
Proteomics (Atomwise)
(# Cos: 270 | $2.1B)
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$867M (▲653%)
17(▲70%)
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
19
$2.1B
97
3
270
11
Atomwise
(2012, United States, $175M)
ProteinSimple
(2004, United States, $94.3M)
AbSci
(2011, United States, $223M)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.

17. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
CureVac (2000, Germany)
$343M - Series F - Jun 2020
CureVac (2000, Germany)
$171M - Series F - Jul 2020
CureVac (2000, Germany)
$126M - Series F - Jul 2020
Wuhan Newfoss Biotech.. (2008, China)
$62.0M - Series B - Feb 2021
Stargazer Pha.. (2020, United States)
$57.0M - Series A - Nov 2020
Atsena Therap.. (2020, United States)
$55.0M - Series A - Dec 2020
Kanaph (2019, South Korea)
$21.0M - Series B - Oct 2020
View all 15 Funding Rounds on Tracxn Platform
Ophthalmology > Drugs > Retinal
Disorders
09
17
Back to index
Ophthalmology (Zeiss)
(# Cos: 919 | $10.7B)
Drugs (Adverum Biotechnologies)
(# Cos: 289 | $6.0B)
Retinal Disorders (CureVac)
(# Cos: 50 | $1.5B)
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$856M (▲1006%)
15(▲87.5%)
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
1
$1.5B
31
7
50
6
CureVac
(2000, Germany, $975M)
Rezolute
(2012, United States)
Molecular Partners
(2004, Switzerland, $59.9M)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.

18. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
Life Sciences Platforms and Tools >
Diversified
10
18
Back to index
Life Sciences Platforms and Tools (Illumina)
(# Cos: 9346 | $48.0B)
Diversified (Thermo Fisher Scientific)
(# Cos: 1136 | $3.3B)
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$783M (▲158%)
18(▼18.2%)
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
118
$3.3B
325
37
1136
23
Thermo Fisher Scientific
(1956, United States)
Twist Bioscience
(2013, United States, $334M)
Corning
(1851, United States)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.
PHC Holdings (2014, Japan)
$182M - Series D - Mar 2021
Rapid Micro .. (2006, United Kingdom)
$120M - Series E - May 2020
LUMICKS (2014, Netherlands)
$93.4M - Series D - Apr 2021
Rapid Micro .. (2006, United Kingdom)
$81.0M - Series E - Mar 2021
PTM Biolab (2011, China)
$80.1M - Series B - Nov 2020
Trucode Gene .. (2016, United States)
$80.0M - Series C - Jan 2021
Encodia (2015, United States)
$75.0M - Series C - Jan 2021
View all 18 Funding Rounds on Tracxn Platform

19. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
Flame Bioscie.. (2019, United States)
$100M - Series B - Sep 2020
Vera Therapeu.. (2016, United States)
$80.0M - Series C - Jan 2021
Escient Pharm.. (2017, United States)
$77.5M - Series B - Sep 2020
NodThera (2016, United Kingdom)
$55.0M - Series B - Jun 2020
Immune Regul.. (2011, United Kingdom)
$52.4M - Series B - Sep 2020
Be Bio (2020, United States)
$52.0M - Series A - Oct 2020
Nereid (1999, United States)
$50.0M - Series A - Nov 2020
View all 27 Funding Rounds on Tracxn Platform
Inflammatory Diseases Drugs
11
19
Back to index
Immunology (GigaGen)
(# Cos: 786 | $17.4B)
Drugs (Moderna)
(# Cos: 655 | $16.6B)
Inflammatory Diseases (RedHill
Biopharma)
(# Cos: 212 | $3.1B)
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$691M (▲216%)
27(▲68.8%)
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
22
$3.1B
154
20
212
23
RedHill Biopharma
(2009, Israel, $13.5M)
Inflazome
(2016, Ireland, $65.0M)
Gossamer Bio
(2017, United States, $330M)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.

20. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
COVID-19 Drugs
12
20
Back to index
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$681M (▲5578%)
14(▲1300%)
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
2
$900M
27
3
50
8
Infectious Diseases (Oxford Immunotec)
(# Cos: 1771 | $25.5B)
Drugs (CureVac)
(# Cos: 992 | $21.1B)
Viral (Moderna)
(# Cos: 424 | $11.5B)
COVID-19 (GigaGen)
(# Cos: 50 | $900M)
GigaGen
(2011, United States, $36.1M)
NantKwest
(2002, United States, $147M)
Tonix Pharma
(2007, United States, $4.5M)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.
Adagio (2020, United States)
$336M - Series C - Apr 2021
Nano (2003, United States)
$90.0M - Series C - Mar 2021
Adagio (2020, United States)
$80.0M - Series B - Nov 2020
Adagio (2020, United States)
$50.0M - Series A - Jul 2020
ExeVir Bio (2020, Belgium)
$27.0M - Series A - Jul 2020
Vaxxinity (2019, United States)
$27.0M - Series B - Mar 2021
ExeVir Bio (2020, Belgium)
$22.7M - Series A - Mar 2021
View all 14 Funding Rounds on Tracxn Platform

21. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
Annexon (2011, United States)
$102M - Series D - Jul 2020
Athira Pharma (2011, United States)
$89.0M - Series B - Jun 2020
LEXEO Therape.. (2018, United States)
$85.0M - Series A - Jan 2021
Pipeline Ther.. (2017, United States)
$80.0M - Series C - Feb 2021
Autobahn Ther.. (2019, United States)
$76.0M - Series B - Jun 2020
ESCAPE Bio (2015, United States)
$73.0M - Series C - Sep 2020
BioShin (2018, China)
$60.0M - Series A - Sep 2020
View all 37 Funding Rounds on Tracxn Platform
Neurodegenerative Disorders Drugs
13
21
Back to index
Neurology (Biohaven Pharmaceutical)
(# Cos: 2243 | $26.0B)
Drugs (Zogenix)
(# Cos: 1215 | $19.7B)
Neurodegenerative (Biogen)
(# Cos: 454 | $6.6B)
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$606M (▲16.2%)
37(▲23.3%)
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
29
$6.6B
307
46
454
43
Biogen
(1978, United States, $80.0M)
Yumanity Therapeutics
(2014, United States, $51.0M)
Frequency Therapeutics
(2015, United States, $147M)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.

22. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
Freenome (2014, United States)
$270M - Series C - Aug 2020
Goldfinch (2016, United States)
$100M - Series B - Jun 2020
Denovo Biopha.. (2013, United States)
$83.3M - Series C - Jun 2020
Tango Therape.. (2017, United States)
$50.0M - Series B - Aug 2020
Denovo Biopha.. (2013, United States)
$45.9M - Series D - Dec 2020
Metabolon (2000, United States)
$21.8M - Series G - Sep 2020
NeoPhore (2017, United Kingdom)
$21.0M - Series B - Mar 2021
View all 8 Funding Rounds on Tracxn Platform
Genomic Biomarker Discovery Research
14
22
Back to index
Genomics (Illumina)
(# Cos: 6764 | $72.3B)
Genomics Research (eGenesis Bio)
(# Cos: 163 | $3.4B)
Biomarker Discovery (Freenome)
(# Cos: 74 | $2.4B)
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$593M (▲65%)
8(▼11.1%)
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
7
$2.4B
44
5
74
11
Freenome
(2014, United States, $508M)
Metabolon
(2000, United States, $148M)
Lexicon Pharmaceuticals
(1995, United States)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.

23. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
Proteomic Based Diagnostic Tests
15
23
Back to index
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$526M (▲592%)
7(▲40%)
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
5
$1.3B
44
4
87
6
Diagnostics (by Technology) (Medtronic)
(# Cos: 5484 | $42.1B)
Diagnostic Assays and Systems (MyHeritage)
(# Cos: 1616 | $19.6B)
In vitro Diagnostics (Illumina)
(# Cos: 1596 | $19.6B)
Protein-based (Oxford Immunotec)
(# Cos: 363 | $2.8B)
Proteomics (Somalogic)
(# Cos: 87 | $1.3B)
Somalogic
(1999, United States, $664M)
IsoPlexis
(2012, United States, $186M)
20/20 Gene Systems
(2000, United States, $8.3M)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.
Somalogic (1999, United States)
$212M - Series E - Dec 2020
Somalogic (1999, United States)
$121M - Series E - Nov 2020
Sera Prognost.. (2008, United States)
$100M - Series E - Apr 2021
IsoPlexis (2012, United States)
$92.5M - Series D - Jan 2021
Travera (2017, United States)
$8.4M - Series A - Apr 2021
Mursla (2017, United Kingdom)
$547K - Seed - Sep 2020
Inbiomotion (2010, Spain)
Undisclosed - Series A - Jan 2021

24. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
Infectious Diseases > Drugs > Bacterial > Drug
Resistant Infections
16
24
Back to index
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$499M (▲207%)
16(▼30.4%)
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
22
$3.5B
155
22
206
20
Infectious Diseases (Oxford Immunotec)
(# Cos: 1771 | $25.5B)
Drugs (Moderna)
(# Cos: 992 | $21.1B)
Bacterial (Locus Biosciences)
(# Cos: 326 | $5.3B)
Drug Resistant Infections (Paratek
Pharma)
(# Cos: 206 | $3.5B)
Paratek Pharma
(1996, United States, $96.5M)
Locus Biosciences
(2015, United States, $32.3M)
Bioversys
(2008, Switzerland, $28.4M)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.
Everest Medic.. (2017, United States)
$260M - Series C - Jun 2020
MicuRx Pharma.. (2007, United States)
$107M - Series E - Dec 2020
Adaptive Phag.. (2016, United States)
$40.8M - Series B - May 2021
Vedanta Biosc.. (2010, United States)
$25.0M - Series D - Jan 2021
Bioversys (2008, Switzerland)
$21.0M - Series B - Sep 2020
Phico Therap.. (2000, United Kingdom)
$9.9M - Series A - May 2021
Pattern Biosc.. (2016, United States)
$9.0M - Series B - Jul 2020
View all 16 Funding Rounds on Tracxn Platform

25. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
Nucleic Acid Sequencing Equipments
17
25
Back to index
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$445M (▲22.8%)
7(▼36.4%)
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
14
$2.7B
39
3
58
6
Life Sciences Platforms and Tools (Thermo Fisher
Scientific)
(# Cos: 9346 | $48.0B)
Instruments (10X Genomics)
(# Cos: 1481 | $7.9B)
Genomics (Nanopore)
(# Cos: 136 | $3.3B)
Nucleic Acid Sequencing (Illumina)
(# Cos: 58 | $2.7B)
Illumina
(1998, United States, $28.0M)
Nanopore
(2005, United Kingdom, $1.3B)
PacBio
(2004, United States, $342M)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.
Nanopore (2005, United Kingdom)
$271M - Series H - May 2021
Nanopore (2005, United Kingdom)
$110M - Series G - Oct 2020
GensKey (2017, China)
$34.3M - Series C - Nov 2020
GenapSys (2010, United States)
$28.5M - Series C - Mar 2021
SimplSeq (2019, United States)
$2.0M - Seed - Apr 2021
GensKey (2017, China)
Undisclosed - Series C - Apr 2021
SeekGene (2015, China)
Undisclosed - Series A - Jan 2021

26. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
Artiva (2018, United States)
$120M - Series B - Feb 2021
Caribou Biosc.. (2011, United States)
$115M - Series C - Mar 2021
Trucode Gene .. (2016, United States)
$80.0M - Series C - Jan 2021
Artiva (2018, United States)
$78.0M - Series A - Jun 2020
Health Gene Technolog.. (2011, China)
$33.4M - Series A - Dec 2020
mRNA (2016, United States)
$10.0M - Seed - Apr 2021
mRNA (2016, United States)
$2.4M - Seed - Aug 2020
Genomics > Genomics Services >
Genome Engineering
18
26
Back to index
Genomics (Illumina)
(# Cos: 6764 | $72.3B)
Genomics Services (Personalis)
(# Cos: 778 | $1.9B)
Genome Engineering (Caribou
Biosciences)
(# Cos: 95 | $542M)
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$439M (▲1057%)
7(▲133%)
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
4
$542M
25
-
95
6
Caribou Biosciences
(2011, United States, $157M)
Artiva
(2018, United States, $198M)
Canopy Biosciences
(2016, United States, $4.5M)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.

27. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
At-Home Preventive Genetic Test Kits
19
27
Back to index
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$436M (▲142%)
7(▼12.5%)
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
8
$1.1B
45
1
181
8
Genomics (Illumina)
(# Cos: 6764 | $72.3B)
Applied Genomics (Adaptive Biotechnologies)
(# Cos: 3530 | $46.1B)
Consumer Genomics (MyHeritage)
(# Cos: 753 | $3.3B)
Proactive Healthcare (Everly
Wellness)
(# Cos: 181 | $1.1B)
Everly Wellness
(2015, United States, $305M)
Color
(2013, United States, $391M)
Viome
(2016, United States, $72.1M)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.
Everly Wellness (2015, United States)
$175M - Series D - Dec 2020
Color (2013, United States)
$167M - Series D - Jan 2021
Everly Wellness (2015, United States)
$75.0M - Series D - Jan 2021
Variant Bio (2018, United States)
$6.1M - Series A - Aug 2020
Digbi Health (2018, United States)
$5.4M - Series A - Mar 2021
GenoPalate (2016, United States)
$4.0M - Series A - Dec 2020
Viome (2016, United States)
$3.0M - Series B - Feb 2021

28. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
Robotic Surgery Instruments
20
28
Back to index
Surgical Instruments (TransEnterix)
(# Cos: 612 | $5.1B)
Robotic Surgery (Intuitive)
(# Cos: 136 | $3.0B)
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$425M (▲0.2%)
14( <> 0% )
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
18
$3.0B
86
12
136
18
Intuitive
(1995, United States, $47.0M)
TransEnterix
(2006, United States, $96.2M)
CMR Surgical
(2014, United Kingdom, $427M)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.
Memic Surgery (2013, Israel)
$96.0M - Series D - Apr 2021
Edge Medical Robotics (2017, China)
$92.6M - Series B - Jan 2021
PROCEPT BioRo.. (2009, United States)
$77.0M - Series C - Aug 2020
ColubrisMX (2017, United States)
$69.0M - Series B - May 2021
Remebot (2015, China)
$65.7M - Series D - Dec 2020
Activ Surgical (2017, United States)
$15.0M - Series B - Jun 2020
NDR Medical Techn.. (2014, Singapore)
$5.8M - Series A - Jul 2020
View all 14 Funding Rounds on Tracxn Platform

29. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
Ophthalmology Drugs
21
29
Back to index
Ophthalmology (Zeiss)
(# Cos: 919 | $10.7B)
Drugs (CureVac)
(# Cos: 289 | $6.0B)
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$392M (▲89.5%)
34(▲41.7%)
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
36
$6.0B
210
43
289
37
CureVac
(2000, Germany, $975M)
Adverum Biotechnologies
(2006, United States, $70.8M)
Rezolute
(2012, United States)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.
CureVac (2000, Germany)
$343M - Series F - Jun 2020
CureVac (2000, Germany)
$171M - Series F - Jul 2020
Gyroscope (2016, United Kingdom)
$148M - Series C - Mar 2021
CureVac (2000, Germany)
$126M - Series F - Jul 2020
Wuhan Newfoss Biotech.. (2008, China)
$62.0M - Series B - Feb 2021
Stargazer Pha.. (2020, United States)
$57.0M - Series A - Nov 2020
Oculis (2003, Switzerland)
$57.0M - Series C - May 2021
View all 34 Funding Rounds on Tracxn Platform

30. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
Precision Medicine Software
22
30
Back to index
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$386M (▲786%)
6(▲100%)
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
1
$717M
15
1
24
4
Diagnostics (by Technology) (Illumina)
(# Cos: 5484 | $42.1B)
Diagnostic Software (Ibex)
(# Cos: 631 | $4.6B)
Bioinformatics (PierianDx)
(# Cos: 109 | $1.3B)
Precision Medicine (N-of-One)
(# Cos: 58 | $802M)
Therapy Selection (Syapse)
(# Cos: 24 | $717M)
Syapse
(2008, United States, $188M)
N-of-One
(2008, United States, $17.8M)
Turbine
(2015, Hungary, $11.0M)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.
3DMed (2010, China)
$224M - Series D - Oct 2020
Syapse (2008, United States)
$68.0M - Series E - Feb 2021
NovellusDx (2011, Israel)
$57.0M - Series C - Sep 2020
Syapse (2008, United States)
$30.0M - Series E - May 2020
Turbine (2015, Hungary)
$6.8M - Seed - Jan 2021
3DMed (2010, China)
Undisclosed - Series C - Oct 2020

31. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
High-Throughput DNA Sequencing
Instruments
23
31
Back to index
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$381M (▲149%)
2(▼33.3%)
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
-
$1.7B
3
1
3
1
Biotech R&D (Thermo Fisher Scientific)
(# Cos: 1146 | $8.0B)
Instrument Systems (10X Genomics)
(# Cos: 126 | $3.2B)
DNA Sequencing Platforms (PacBio)
(# Cos: 3 | $1.7B)
HT Sequencing Platforms
(Nanopore)
(# Cos: 3 | $1.7B)
Nanopore
(2005, United Kingdom, $1.3B)
PacBio
(2004, United States, $342M)
Nabsys
(2004, United States, $107M)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.
Nanopore (2005, United Kingdom)
$271M - Series H - May 2021
Nanopore (2005, United Kingdom)
$110M - Series G - Oct 2020

32. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
Everest Medic.. (2017, United States)
$260M - Series C - Jun 2020
Affinivax (2013, United States)
$226M - Series C - Jan 2021
MicuRx Pharma.. (2007, United States)
$107M - Series E - Dec 2020
Minervax (2010, Denmark)
$57.4M - Series B - Dec 2020
Adaptive Phag.. (2016, United States)
$40.8M - Series B - May 2021
SpyBiotech (2017, United Kingdom)
$32.5M - Series A - Feb 2021
Adrenomed (2009, Germany)
$26.6M - Series E - Nov 2020
View all 26 Funding Rounds on Tracxn Platform
Antibacterial Drugs
24
32
Back to index
Infectious Diseases (Oxford Immunotec)
(# Cos: 1771 | $25.5B)
Drugs (Moderna)
(# Cos: 992 | $21.1B)
Bacterial (Paratek Pharma)
(# Cos: 326 | $5.3B)
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$380M (▲46.6%)
26(▼16.1%)
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
34
$5.3B
238
36
326
33
Paratek Pharma
(1996, United States, $96.5M)
Locus Biosciences
(2015, United States, $32.3M)
Symbiomix Therapeutics
(2012, United States, $66.5M)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.

33. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
Caribou Biosc.. (2011, United States)
$115M - Series C - Mar 2021
Alchemab (2019, United Kingdom)
$82.7M - Series A - Apr 2021
Touchlight (2008, United Kingdom)
$58.4M - Series B - Mar 2021
Clear Labs (2014, United States)
$39.5M - Series B - May 2020
Health Gene Technolog.. (2011, China)
$33.4M - Series A - Dec 2020
Trace Genomics (2015, United States)
$17.2M - Series B - Jul 2020
Hangzhou Lianchuan Bi.. (2006, China)
$16.2M - Series B - Jun 2020
View all 23 Funding Rounds on Tracxn Platform
Life Sciences Platforms and Tools > Research
Services > Genomics
25
33
Back to index
Life Sciences Platforms and Tools (Illumina)
(# Cos: 9346 | $48.0B)
Research Services (Ginkgo Bioworks)
(# Cos: 4917 | $32.8B)
Genomics (Personalis)
(# Cos: 623 | $1.9B)
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$367M (▲39.7%)
23(▲4.5%)
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
53
$1.9B
190
16
623
19
Personalis
(2011, United States, $87.3M)
Ancestry
(1996, United States, $146M)
Syngenta
(2000, Switzerland)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.

34. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
Forge Biologics (2020, United States)
$120M - Series B - Apr 2021
Annexon (2011, United States)
$102M - Series D - Jul 2020
Terns Pharmac.. (2017, United States)
$97.7M - Series C - Jan 2021
Forge Biologics (2020, United States)
$40.0M - Series A - Jul 2020
Rare Autoimmune Disorders Drugs
26
34
Back to index
Rare Diseases (Moderna)
(# Cos: 477 | $19.3B)
Drugs (Alexion)
(# Cos: 462 | $19.3B)
Autoimmune Diseases (Terns
Pharmaceutical)
(# Cos: 14 | $1.6B)
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$360M ( -- )
4( -- )
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
1
$1.6B
10
5
14
1
Terns Pharmaceutical
(2017, United States, $208M)
Rigel
(1996, United States)
Annexon
(2011, United States, $256M)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.

35. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
Proteomics Based Drug Discovery
Software
27
35
Back to index
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$355M (▲188%)
10(▲42.9%)
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
11
$875M
44
1
101
8
Life Sciences Tech (Veeva Systems)
(# Cos: 4054 | $19.2B)
Research & Development (Medidata)
(# Cos: 3250 | $16.0B)
Drug Discovery (Illumina)
(# Cos: 934 | $8.6B)
Proteomics (Seer)
(# Cos: 101 | $875M)
Seer
(2017, United States, $128M)
Vividion Therapeutics
(2016, United States, $271M)
Cyrus Biotechnology
(2014, United States, $10.9M)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.
Eikon (2019, United States)
$148M - Series A - May 2021
Vividion Ther.. (2016, United States)
$135M - Series C - Feb 2021
Frontier Medi.. (2018, United States)
$67.0M - Series A - Nov 2020
Seer (2017, United States)
$55.0M - Series D - Jul 2020
Rapid Novor (2015, Canada)
$5.0M - Series A - Jul 2020
Menten (2018, Canada)
$4.0M - Seed - Jun 2020
Ecto (2013, United States)
$3.0M - Seed - May 2021
View all 10 Funding Rounds on Tracxn Platform

36. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
Diagnostics (by Technology) > Diagnostic Assays and Systems
> In vitro Diagnostics > Multi-omic Assays > Liquid Biopsy
28
36
Back to index
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$352M (▲80.3%)
2(▼66.7%)
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
1
$874M
9
4
14
2
Diagnostics (by Technology) (Medtronic)
(# Cos: 5484 | $42.1B)
Diagnostic Assays and Systems (MyHeritage)
(# Cos: 1616 | $19.6B)
In vitro Diagnostics (Illumina)
(# Cos: 1596 | $19.6B)
Multi-omic Assays (Biodesix)
(# Cos: 32 | $1.1B)
Liquid Biopsy (Freenome)
(# Cos: 14 | $874M)
Freenome
(2014, United States, $508M)
Biodesix
(2005, United States, $190M)
Biocept
(1993, United States, $53.1M)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.
Freenome (2014, United States)
$270M - Series C - Aug 2020
Scipher Medic.. (2014, United States)
$82.0M - Series C - Mar 2021

37. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
Diabetes Drugs
29
37
Back to index
Diabetes (Livongo)
(# Cos: 803 | $8.7B)
Drugs (Pendulum)
(# Cos: 224 | $4.4B)
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$333M (▼22.1%)
22(▲10%)
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
18
$4.4B
154
23
224
21
Pendulum
(2012, United States, $57.0M)
Rezolute
(2012, United States)
Ocugen
(2013, United States, $18.9M)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.
Kriya Therape.. (2012, United States)
$85.6M - Series A - May 2020
ViaCyte (1999, United States)
$53.9M - Series E - Apr 2021
Carmot Therap.. (2010, United States)
$47.0M - Series C - Sep 2020
Enthera (2016, Italy)
$32.8M - Series A - Jul 2020
Imcyse (2010, Belgium)
$25.8M - Series B - Feb 2021
Glyscend (2014, United States)
$20.5M - Series A - Jun 2020
Elevian (2017, United States)
$15.3M - Series A - Jul 2020
View all 22 Funding Rounds on Tracxn Platform

38. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
Orca Bio (2016, United States)
$192M - Series D - Jul 2020
Talaris (2019, United States)
$115M - Series B - Oct 2020
Polyneuron (2014, Switzerland)
$15.4M - Series A - Sep 2020
ActiTrexx (2020, Germany)
$4.2M - Series A - Mar 2021
Immunology > Drugs > GvHD
30
38
Back to index
Immunology (DBV Technologies)
(# Cos: 786 | $17.4B)
Drugs (Moderna)
(# Cos: 655 | $16.6B)
GvHD (GigaGen)
(# Cos: 16 | $623M)
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$327M ( -- )
4( -- )
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
3
$623M
13
2
16
5
GigaGen
(2011, United States, $36.1M)
Polyneuron
(2014, Switzerland, $40.2M)
Orca Bio
(2016, United States, $192M)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.

39. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
LianBio (1999, China)
$310M - Series D - Oct 2020
LianBio (1999, China)
$3.0M - Series D - Apr 2021
Cardiac and Vascular Disorders > Drugs >
Valvular Disorders
31
39
Back to index
Cardiac and Vascular Disorders (Eko)
(# Cos: 2244 | $28.8B)
Drugs (Moderna)
(# Cos: 309 | $9.5B)
Valvular Disorders (LianBio)
(# Cos: 2 | $313M)
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$313M ( -- )
2( -- )
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
-
$313M
2
-
2
1
LianBio
(1999, China, $313M)
Spark Biopharma
(2016, South Korea)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.

40. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
R&D Workflow Management Solutions
32
40
Back to index
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$295M (▲587%)
3( <> 0% )
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
2
$437M
15
-
45
2
Life Sciences Tech (Medidata)
(# Cos: 4054 | $19.2B)
Research & Development (Illumina)
(# Cos: 3250 | $16.0B)
Drug Informatics (NantHealth)
(# Cos: 613 | $3.2B)
R&D Workflow Management
(Benchling)
(# Cos: 45 | $437M)
Benchling
(2012, United States, $350M)
Curoverse
(2010, United States, $1.7M)
Vyasa
(2016, United States)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.
Benchling (2012, United States)
$200M - Series E - Apr 2021
Benchling (2012, United States)
$50.0M - Series D - May 2020
Standigm (2015, South Korea)
$44.5M - Series C - Mar 2021

41. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
Neurogene (2001, United States)
$115M - Series B - Dec 2020
Autobahn Ther.. (2019, United States)
$76.0M - Series B - Jun 2020
Longboard Pha.. (2020, United States)
$56.0M - Series C - Oct 2020
Alcyone Life .. (2010, United States)
$17.6M - Series C - Sep 2020
Polyneuron (2014, Switzerland)
$15.4M - Series A - Sep 2020
Retrotope (2008, United States)
$13.3M - Series D - Jan 2021
Reflection T.. (2018, United Kingdom)
$181K - Seed - Aug 2020
Rare Neurological Disease Drugs
33
41
Back to index
Rare Diseases (Moderna)
(# Cos: 477 | $19.3B)
Drugs (Alexion)
(# Cos: 462 | $19.3B)
CNS (MindMed)
(# Cos: 47 | $1.3B)
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$294M (▲54.2%)
7(▼22.2%)
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
6
$1.3B
34
11
47
6
MindMed
(2019, Canada)
QurAlis
(2016, United States, $47.5M)
Engage Therapeutics
(2017, United States, $30.6M)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.

42. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
Olena Pharma (2007, United States)
$87.4M - Series C - Oct 2020
Olema Oncology (2007, United States)
$85.0M - Series C - Oct 2020
Olema Oncology (2007, United States)
$54.0M - Series B - Jul 2020
Olena Pharma (2007, United States)
$53.9M - Series B - Jun 2020
Shorla Pharma (2017, Ireland)
$8.3M - Series A - Jun 2020
Oncology > Drugs > Breast Cancer
34
42
Back to index
Oncology (Adaptive Biotechnologies)
(# Cos: 4068 | $85.2B)
Drugs (Moderna)
(# Cos: 2628 | $66.0B)
Breast Cancer (Atossa Therapeutics)
(# Cos: 18 | $787M)
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$289M (▲78.7%)
5(▲150%)
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
-
$787M
13
6
18
5
Atossa Therapeutics
(2009, United States, $6.7M)
Olena Pharma
(2007, United States, $147M)
Daré Bioscience
(2005, United States)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.

43. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
Diagnostics (by Technology) > Diagnostic
Software > Imaging > Digital Pathology
35
43
Back to index
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$282M (▲327%)
10( <> 0% )
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
6
$683M
42
2
81
8
Diagnostics (by Technology) (Illumina)
(# Cos: 5484 | $42.1B)
Diagnostic Software (PierianDx)
(# Cos: 631 | $4.6B)
Imaging (PathAI)
(# Cos: 361 | $2.8B)
Digital Pathology (Ibex)
(# Cos: 81 | $683M)
Ibex
(2016, Israel, $52.0M)
PathAI
(2016, United States, $89.9M)
PAIGE
(2018, United States, $266M)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.
PAIGE (2018, United States)
$100M - Series C - Jan 2021
PAIGE (2018, United States)
$71.0M - Series B - Jul 2020
Ibex (2016, Israel)
$38.0M - Series B - Mar 2021
PAIGE (2018, United States)
$25.0M - Series C - Mar 2021
Proscia (2014, United States)
$23.0M - Series B - Nov 2020
CoreMap (2017, United States)
$10.5M - Series A - Sep 2020
Perimeter Medical Im.. (2013, Canada)
$7.3M - Series B - Jul 2020
View all 10 Funding Rounds on Tracxn Platform

44. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
Digital Pathology Image Analysis
Software
36
44
Back to index
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$277M (▲515%)
8(▲300%)
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
9
$557M
26
-
76
6
Life Sciences Tech (Medidata)
(# Cos: 4054 | $19.2B)
Research & Development (Illumina)
(# Cos: 3250 | $16.0B)
Image Analysis (MEDIAN Technologies)
(# Cos: 192 | $918M)
Digital Pathology (PAIGE)
(# Cos: 76 | $557M)
PAIGE
(2018, United States, $266M)
Visiopharm
(2001, Denmark, $26.3M)
Proscia
(2014, United States, $35.0M)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.
PAIGE (2018, United States)
$100M - Series C - Jan 2021
PAIGE (2018, United States)
$71.0M - Series B - Jul 2020
PAIGE (2018, United States)
$25.0M - Series C - Mar 2021
Resolve Biosciences (2020, Germany)
$24.0M - Series A - Dec 2020
Proscia (2014, United States)
$23.0M - Series B - Nov 2020
Deepcell (2015, United States)
$20.0M - Series A - Dec 2020
Visiopharm (2001, Denmark)
$7.5M - Series B - Jul 2020
View all 8 Funding Rounds on Tracxn Platform

45. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
Valvular Disorder Therapy Devices
37
45
Back to index
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$275M (▲10.6%)
13(▲8.3%)
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
23
$2.7B
93
4
124
20
Cardiac and Vascular Disorders (Moderna)
(# Cos: 2244 | $28.8B)
Medical Devices (Eko)
(# Cos: 1786 | $18.4B)
Therapeutic Devices (AtriCure)
(# Cos: 971 | $14.1B)
Valvular Diseases (Edwards
Lifesciences)
(# Cos: 124 | $2.7B)
Edwards Lifesciences
(1958, United States)
JenaValve Technology
(2006, United States, $247M)
Symetis
(2001, Switzerland, $56.7M)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.
Shanghai New Pulse Me.. (2015, China)
$100M - Series C - Mar 2021
Polares Medical (2017, Switzerland)
$40.0M - Series B - Jun 2020
Neochord (2007, United States)
$33.4M - Series E - Feb 2021
Innovheart (2015, Italy)
$23.7M - Series B - Aug 2020
Foldax (2006, United States)
$20.0M - Series D - Jun 2020
CardioMech (2015, Norway)
$18.5M - Series A - Aug 2020
Cardiac Dimen.. (2001, United States)
$17.5M - Series C - Sep 2020
View all 13 Funding Rounds on Tracxn Platform

46. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
Diagnostics (by Technology) > Diagnostic Assays and Systems > In vitro
Diagnostics > Cell or Tissue-based > Liquid Biopsy > Circulating Tumor
Cells
38
46
Back to index
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$273M (▲110%)
3(▼40%)
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
4
$644M
22
3
35
3
Diagnostics (by Technology) (Medtronic)
(# Cos: 5484 | $42.1B)
Diagnostic Assays and Systems (MyHeritage)
(# Cos: 1616 | $19.6B)
In vitro Diagnostics (Illumina)
(# Cos: 1596 | $19.6B)
Cell or Tissue-based (Epic Sciences)
(# Cos: 146 | $1.9B)
Liquid Biopsy (Exosome Diagnostics)
(# Cos: 51 | $1.0B)
Circulating Tumor Cells (Thrive
Earlier Detection)
(# Cos: 35 | $644M)
Thrive Earlier Detection
(2019, United States, $367M)
Epic Sciences
(2008, United States, $138M)
ApoCell
(2004, United States)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.
Thrive Earlie.. (2019, United States)
$257M - Series B - Jul 2020
Polaris Biology (2016, China)
$9.9M - Series B - Jun 2020
Biofluidica (2007, United States)
$6.0M - Series B - Mar 2021

47. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
Genomics Based Drug Discovery
Software
39
47
Back to index
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$270M (▲472%)
8(▲60%)
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
3
$1.1B
41
2
101
8
Life Sciences Tech (Veeva Systems)
(# Cos: 4054 | $19.2B)
Research & Development (Medidata)
(# Cos: 3250 | $16.0B)
Drug Discovery (Recursion)
(# Cos: 934 | $8.6B)
Genomics (Illumina)
(# Cos: 548 | $3.2B)
Drug Development (Insilico)
(# Cos: 101 | $1.1B)
Insilico
(2014, China, $49.8M)
Arrakis Therapeutics
(2015, United States, $113M)
DNAnexus
(2009, United States, $273M)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.
LinkDoc (2014, China)
$102M - Series D - Sep 2020
DNAnexus (2009, United States)
$100M - Series G - Jun 2020
Octant (2017, United States)
$30.0M - Series A - May 2020
Brightseed (2018, United States)
$27.0M - Series B - Sep 2020
Phenomic AI (2017, Canada)
$6.0M - Seed - Oct 2020
Kinomica (2017, United Kingdom)
$5.2M - Series A - Dec 2020
Xbiome (2019, China)
Undisclosed - Series B - Dec 2020
View all 8 Funding Rounds on Tracxn Platform

48. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
Biocytogen (2008, United States)
$142M - Series D - Sep 2020
eGenesis Bio (2014, United States)
$125M - Series C - Mar 2021
Ten Bio (2019, United Kingdom)
$1.3M - Seed - Apr 2021
Hera Biolabs (2015, United States)
$1.1M - Series A - Aug 2020
Cellaria Bios.. (2013, United States)
$150K - Seed - May 2020
Life Sciences Platforms and Tools > Research
Services > Animal Models
40
48
Back to index
Life Sciences Platforms and Tools (Illumina)
(# Cos: 9346 | $48.0B)
Research Services (Ginkgo Bioworks)
(# Cos: 4917 | $32.8B)
Animal Models (eGenesis Bio)
(# Cos: 85 | $788M)
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$268M (▲48.5%)
5(▼28.6%)
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
3
$788M
37
3
85
5
eGenesis Bio
(2014, United States, $265M)
Biocytogen
(2008, United States, $291M)
Applied StemCell
(2008, United States, $67.5M)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.

49. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
Biocytogen (2008, United States)
$142M - Series D - Sep 2020
eGenesis Bio (2014, United States)
$125M - Series C - Mar 2021
Genomics > Genomics Research >
Research Models
41
49
Back to index
Genomics (Illumina)
(# Cos: 6764 | $72.3B)
Genomics Research (Freenome)
(# Cos: 163 | $3.4B)
Research Models (eGenesis Bio)
(# Cos: 44 | $601M)
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$267M (▲48.8%)
2(▼50%)
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
8
$601M
20
3
44
2
eGenesis Bio
(2014, United States, $265M)
Biocytogen
(2008, United States, $291M)
GenOway
(1999, France, $11.6M)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.

50. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
Goldfinch (2016, United States)
$100M - Series B - Jun 2020
Pharvaris (2015, Netherlands)
$80.0M - Series C - Nov 2020
Palladio Bios.. (2016, United States)
$28.0M - Series B - Sep 2020
Attralus (2019, United States)
$25.0M - Series A - Sep 2020
ILIAS Biologics (2015, South Korea)
$20.6M - Series B - Sep 2020
Immusoft (2009, United States)
$10.3M - Series B - Mar 2021
Gain Therapeutics (2017, Switzerland)
$10.0M - Series B - Jul 2020
View all 18 Funding Rounds on Tracxn Platform
Rare Metabolic Disorder Drugs
42
50
Back to index
Rare Diseases (Recursion)
(# Cos: 477 | $19.3B)
Drugs (Alexion)
(# Cos: 462 | $19.3B)
Metabolic Disorders (Moderna)
(# Cos: 155 | $6.9B)
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$267M (▼41.9%)
18( <> 0% )
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
27
$6.9B
119
28
155
14
Moderna
(2010, United States, $2.8B)
Synlogic Therapeutics
(2013, United States, $34.4M)
Catabasis Pharmaceutic..
(2008, United States, $116M)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.

51. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
Molecular Modeling Solutions
43
51
Back to index
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$260M (▲150%)
10(▲42.9%)
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
2
$712M
44
-
109
4
Life Sciences Tech (Medidata)
(# Cos: 4054 | $19.2B)
Research & Development (Illumina)
(# Cos: 3250 | $16.0B)
Drug Informatics (Benchling)
(# Cos: 613 | $3.2B)
Molecular Modeling (Benevolent
AI)
(# Cos: 109 | $712M)
Benevolent AI
(2013, United Kingdom, $282M)
Novadiscovery
(2010, France, $8.6M)
Cellarity
(2015, United States, $173M)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.
Cellarity (2015, United States)
$123M - Series B - Feb 2021
Stonewise (2018, China)
$100M - Series B - Apr 2021
Reverie Labs (2017, United States)
$25.0M - Series A - Feb 2021
Enveda (2019, United States)
$4.9M - Seed - Dec 2020
Novadiscovery (2010, France)
$3.0M - Series A - Feb 2021
PharmEnable (2016, United Kingdom)
$2.2M - Seed - Jun 2020
Ten63 (2019, United States)
$2.1M - Seed - Jan 2021
View all 10 Funding Rounds on Tracxn Platform

52. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
Genomics > Applied Genomics > Clinical Genomics >
Diagnostics > Sequencing-based > Genetic Diagnosis > Suite
44
52
Back to index
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$257M (▲2593%)
6(▲100%)
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
6
$461M
19
-
76
4
Genomics (Illumina)
(# Cos: 6764 | $72.3B)
Applied Genomics (MyHeritage)
(# Cos: 3530 | $46.1B)
Clinical Genomics (Hologic)
(# Cos: 1775 | $34.5B)
Diagnostics (Invitae)
(# Cos: 1258 | $22.8B)
Sequencing-based (Guardant Health)
(# Cos: 1043 | $21.2B)
Genetic Diagnosis (Adaptive
Biotechnologies)
(# Cos: 332 | $3.1B)
Suite (Igenomix)
(# Cos: 76 | $461M)
Igenomix
(2009, Spain)
Variantyx
(2014, United States, $27.0M)
Sema4
(2017, United States, $241M)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.
Sema4 (2017, United States)
$121M - Series C - Jul 2020
Guangzhou Kang Liming.. (2015, China)
$88.0M - Series C - Sep 2020
Variantyx (2014, United States)
$20.0M - Series C - Mar 2021
Beijing Zhiyin Dongfang (2009, China)
$15.5M - Series B - Feb 2021
Lilac Insights (2011, India)
$6.9M - Series A - Feb 2021
Veritas Intercontinen.. (2014, Spain)
$5.9M - Series B - Sep 2020

53. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
Pharmocogenomic Tests
45
53
Back to index
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$250M (▲ >10K%)
4(▲33.3%)
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
10
$992M
41
5
93
7
Diagnostics (by Technology) (Medtronic)
(# Cos: 5484 | $42.1B)
Diagnostic Assays and Systems (Invitae)
(# Cos: 1616 | $19.6B)
In vitro Diagnostics (Guardant Health)
(# Cos: 1596 | $19.6B)
Nucleic Acid-based (Adaptive
Biotechnologies)
(# Cos: 878 | $13.1B)
Sequencing-based (MyHeritage)
(# Cos: 660 | $10.4B)
Genomics (Illumina)
(# Cos: 613 | $9.8B)
Pharmacogenomics
(Foundation Medicine)
(# Cos: 93 | $992M)
Foundation Medicine
(2010, United States, $96.5M)
Caris Life Sciences
(1996, United States, $235M)
Interleukin Genetics
(1986, United States, $33.6M)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.
Caris Life Sc.. (1996, United States)
$235M - Unattributed - Oct 2020
Genomind (2009, United States)
$6.4M - Series D - Apr 2021
Strata Oncology (2015, United States)
$5.0M - Series B - Nov 2020
AltheaDx (2009, United States)
$3.7M - Series D - Dec 2020

54. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
Genetic Engineering Technologies
46
54
Back to index
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$249M (▲140%)
11(▲175%)
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
3
$841M
39
2
63
7
Genomics (Illumina)
(# Cos: 6764 | $72.3B)
Enabling Technologies (10X Genomics)
(# Cos: 1547 | $16.3B)
Technology Platforms (Moderna)
(# Cos: 346 | $9.0B)
Genetic Engineering (Senti
Biosciences)
(# Cos: 63 | $841M)
Senti Biosciences
(2016, United States, $158M)
GreenLight Biosciences
(2009, United States, $215M)
Tmunity Therapeutics
(2015, United States, $231M)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.
Senti Bioscie.. (2016, United States)
$105M - Series B - Jan 2021
GreenLight Bi.. (2009, United States)
$102M - Series D - Jun 2020
LabGenius (2012, United Kingdom)
$15.0M - Series A - Oct 2020
Geninus (2018, South Korea)
$13.3M - Series B - Aug 2020
ADARx Pharmac.. (2019, United States)
$6.0M - Series A - Nov 2020
ADARx Pharmac.. (2019, United States)
$5.0M - Series A - Aug 2020
Twelve Bio (2019, Denmark)
$2.6M - Seed - Sep 2020
View all 11 Funding Rounds on Tracxn Platform

55. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
Dyne Therapeu.. (2018, United States)
$116M - Series B - Aug 2020
AAVANTIBio (2017, United States)
$107M - Series A - Oct 2020
Knopp Bioscie.. (2005, United States)
$12.6M - Series D - Oct 2020
Versameb (2017, Switzerland)
$6.4M - Seed - Jul 2020
ARTHEx (2018, Spain)
$4.9M - Series A - Jul 2020
Knopp Bioscie.. (2005, United States)
Undisclosed - Series D - Nov 2020
ARTHEx (2018, Spain)
Undisclosed - Seed - Jun 2020
Neromuscular Disorder Drugs
47
55
Back to index
Neurology (Zogenix)
(# Cos: 2243 | $26.0B)
Drugs (Biogen)
(# Cos: 1215 | $19.7B)
Neuromuscular (Scholar Rock)
(# Cos: 35 | $1.1B)
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$247M (▲9.8%)
7(▼36.4%)
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
6
$1.1B
21
3
35
9
Scholar Rock
(2012, United States, $103M)
Dyne Therapeutics
(2018, United States, $166M)
Keros Therapeutics
(2016, United States, $90.0M)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.

56. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
Wound Healing Drugs
48
56
Back to index
Wound Care (Imbed Biosciences)
(# Cos: 522 | $1.8B)
Drugs (Kane Biotech)
(# Cos: 185 | $992M)
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$239M (▲1132%)
11(▲22.2%)
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
19
$992M
126
22
185
9
Kane Biotech
(2001, Canada, $42.5K)
Derma Sciences
(1984, United States, $18.2M)
Ilya Pharma
(2016, Sweden, $3.5M)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.
Endeavor Biom.. (2018, United States)
$62.0M - Series A - Jan 2021
CytoKi Pharma (2019, Denmark)
$45.0M - Series A - May 2021
QBiotics (2000, Australia)
$38.7M - Series C - Mar 2021
Resolution T.. (2017, United Kingdom)
$35.6M - Series A - Dec 2020
Medical Ethics (2004, Australia)
$24.9M - Series B - Feb 2021
CUTISS (2017, Switzerland)
$19.5M - Series B - Jun 2020
Novo Bioscien.. (2013, United States)
$4.0M - Series A - Jun 2020
View all 11 Funding Rounds on Tracxn Platform

57. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
Gastroenterology > Drugs > Bowel Disorders >
Inflammatory Bowel Disorders
49
57
Back to index
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$232M (▲2493%)
6(▲500%)
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
2
$424M
10
3
14
4
Gastroenterology (RedHill Biopharma)
(# Cos: 403 | $4.4B)
Drugs (Ironwood Pharma)
(# Cos: 163 | $2.5B)
Bowel Disorders (Pendulum)
(# Cos: 23 | $603M)
Inflammatory Bowel Disorders
(Enterome)
(# Cos: 14 | $424M)
Enterome
(2011, France, $130M)
Prometheus Biosciences
(2016, United States, $130M)
Aclaris Therapeutics
(2012, United States, $82.0M)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.
Prometheus Bi.. (2016, United States)
$130M - Series D - Nov 2020
Enterome (2011, France)
$52.3M - Series E - Jun 2020
Enthera (2016, Italy)
$32.8M - Series A - Jul 2020
Enthera (2016, Italy)
$8.5M - Series A - Jan 2021
Qu Biologics (2007, Canada)
$8.0M - Series B - Dec 2020
MicrobiomX (2017, United States)
$505K - Seed - Jun 2020

58. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Recent Funding Rounds
VISEN Pharmaceuticals (2018, China)
$150M - Series B - Jan 2021
MBX Biosciences (2018, United States)
$34.6M - Series A - Jul 2020
Siolta Therap.. (2016, United States)
$30.0M - Series B - Sep 2020
Koligo Therap.. (2016, United States)
$1.6M - Seed - Oct 2020
Metabolic Diseases > Drugs > Endocrine
disorders
50
58
Back to index
Metabolic Diseases (Sigilon)
(# Cos: 342 | $9.2B)
Drugs (MannKind Corp)
(# Cos: 230 | $7.7B)
Endocrine disorders (Millendo
Therapeutics)
(# Cos: 28 | $911M)
Taxonomy
$ Invested in last 1 year
Key Stats
# Funding Rounds in last 1 year
$216M (▲108%)
4(▲33.3%)
Funded Companies
Companies
Acquisitions
Total $ Invested
IPOs
Soonicorn Club
5
$911M
23
13
28
4
Millendo Therapeutics
(2012, United States, $128M)
Sigilon
(2015, United States, $195M)
Diurnal
(2004, United Kingdom, $59.7M)
Note: The last node in the Taxonomy represents the Business Model addressed in the title of the slide.

59. Life Sciences - Top Business Models Report Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Recent funding rounds
Investment Trends
Most Active Investors
Top Funded Business Models
Explore more on Tracxn
All Tech Companies
US Tech Companies
Online Travel Companies
Companies using AI in Healthcare
Companies founded by Stanford GSB Alumni
Soonicorn club in Fintech
Analyst Picks in Israel Tech
Key News in FinTech
Events in Bay Area
Angel Investors in United States
Bluebox
Companies Investment Activity
Miscellaneous
Company Detail Page of DoorDash
Competitors of Freshworks
Cap Table for TransferWise
Financials for Ola
Employee Count for Revolut
Company Due Diligence Exits
Public Companies
Acquired Companies
Most Active Acquirers
Reports
Delhivery - Company Report
Novel Foods - Business Model Report
HRTech - Feed Report
FinTech - Top Business Models Report
US Tech - Top Business Models Report
US Tech - Monthly Report
59

60. Life Sciences - Top Business Models Report Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Explore other Reports on Tracxn
HRTech
InsurTech
Food Tech
Novel Foods
Blockchain Network
P2P Remittance
Business Model Reports
FinTech Europe
Consumer Digital SEA
HiTech US
Feed Geo Reports
Company Reports
Monthly Unicorn Report
Unicorn Reports
Transferwise
Coursera
BigBasket
Feed Reports Top Business Models in PA
FinTech
Enterprise Applications
Artificial Intelligence
Geo Monthly Reports
US Tech
Europe Tech
China Tech
Top Business Models in Geo
India Tech
Israel Tech
UK & Ireland Tech
60

61. Copyright © 2021, Tracxn Technologies Private Limited. All rights reserved.
Life Sciences - Top Business Models Report
Any and all information either accessed from the website www.tracxn.com or having otherwise originated from Tracxn Technologies Private Limited including but not limited to the
information contained herein ("Data") is the sole property of Tracxn Technologies Private Limited (hereinafter "Tracxn"). You shall not recirculate, distribute, transmit, publish, or
sell the Data or any portion thereof in any form or by any means, either for commercial or non-commercial use, or permit any third party to use or distribute the Data or any
portion thereof; to any other party, except with the prior written consent of Tracxn. You may however incorporate insubstantial portions, extracts, abstracts or summaries from the
Data into analysis, presentations or tools for your customers or for your internal use, so long as Tracxn is clearly and visibly identified as the source of information.
For further information please refer to our Terms of Use at www.tracxn.com